RadarScreener › BGLC

BGLC

BioNexus Gene Lab Corp
Nasdaq · Services-Medical Laboratories · EDGAR filings (CIK 1737523) · 4 signals · 1 setups · updated Aug 16, 2026

What the filings say Mixed ◆

An activist has arrived at a company that needs cash — a potential catalyst, but any financing terms may favour the newcomer. Support side: New 13D filer — insiders or holders bought while this setup is live; see the timeline.

Radar 61 (elevated attention) · dilution pressure low · listing risk low · governance risk low · runway 12.8 mo · strongest signal: New 13D filer (Aug 14, 2026)

What would confirm: 13D/A with a plan (Item 4), DEFC14A proxy contest, or 8-K 5.02 board seats.
What would prove it wrong: 13D/A showing the position sold down.

Direction is stated for existing shareholders (▼ more shares / survival or listing risk; ▲ insiders or holders buying). It is a characterization of the filings, not a forecast or a recommendation.

61Radar · attention score (0–100)
0Dilution pressure · financing + balance sheet
26Listing risk · exchange standards
33Governance risk · reporting, auditor, going concern

Setups

Independent filings stitched into a thesis, each with what would confirm and what would prove it wrong.

Activist meets distress Mixed ◆ strength 0.55

An activist has arrived at a company that needs cash — a potential catalyst, but any financing terms may favour the newcomer. A new active >5% holder appeared while the company is under cash or listing pressure - the classic precursor to a recapitalization, board change, or takeover at a discount.

Would confirm: 13D/A with a plan (Item 4), DEFC14A proxy contest, or 8-K 5.02 board seats.
Would invalidate: 13D/A showing the position sold down.
New 13D filerGoing-concern language

Analyst note

No note yet. Notes are written each morning for the top-ranked setups; Pro subscribers get them in full the same day.

Pro on BGLC
Alerts
One email the morning BGLC files anything that matches your rules (types, minimum score, setups).
12-month history
Every signal and setup for BGLC back a year, not just 30 days — see how the current setup built.
Full analyst notes
What we noticed, evidence with links, what could prove us wrong, red-team caveats.
Full screener + CSV
All 985 flagged companies, same-day, sortable and exportable.
Get Pro · $18.85/mo founding rate   See a full Pro morning 35% off forever until Sept 30 · cancel any time

Balance sheet (XBRL)

$1.2Mcash + short-term investments as of Jun 30, 2026
12.8 moestimated runway (annualized 180-day YTD operating cash flow [companyfacts])
$7.8Mstockholders' equity as of Jun 30, 2026
$4.8Mpublic float (10-K cover)
2.9Mshares outstanding as of Aug 14, 2026 · was 2.4M May 15, 2026

Runway = liquidity ÷ monthly operating burn at the latest reported period · balance sheet 47 days old. A financing after the balance-sheet date is the main reason a figure can be stale — check the timeline below for offerings since then.

Signal timeline

Last 30 days of filing signals plus current balance-sheet flags, newest first. ▼ pressure · ▲ support · hover a score for its components; every row links to the filing.

DateSignalEvidenceScore
Aug 14, 2026 New 13D filer Schedule 13D filed 2026-08-14 filing 45
Aug 14, 2026 Going-concern language “going concern periodic” language in 10-Q (10-Q) filed 2026-08-14 filing 33
Aug 14, 2026· Form 4 burst 5 Form 4 filings in 30 days filing 15
Jun 30, 2026 Near $5M MVLS floor Public float $4,814,884 (as of 2025-06-30) vs $5M Nasdaq MVLS floor; needs price x shares confirmation filing 26

Other activist + distress setups

KUST KUSTOM ENTERTAINMENT, INC. · BXBL BOXABL Inc. · VBIO Valion Bio, Inc. · ACR ACRES Commercial Realty Corp · VATE INNOVATE Corp. · YARW Yarrow Bioscience, Inc. · screener →

Not a subscriber yet? The free morning digest carries what changed and the top setups. Subscribe free → · Compare plans